We’re so unprepared for finding an Alzheimer’s treatment

Finding an Alzheimer’s drug could be a breakthrough — that leads to a massive wait list......»»

Category: topSource: washpostNov 15th, 2017

Merck (MRK) Halts Another Late Stage Study on Alzheimer"s

Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an .....»»

Category: smallbizSource: nytFeb 14th, 2018

The Quest to Develop the First Alzheimer’s Disease Treatment

The reasons Pfizer recently decided to stop pursuing neurological disease research and what to look forward to in the near future regarding Alzheimer's disease treatmentsRelated Stocks: NVS, GILD, CELG, ONCE, PFE, AXON, MRK, LLY, BIIB, PRAN, JNJ,.....»»

Category: worldSource: nytFeb 13th, 2018

Alzheimer"s Study Discovers Toxic Protein Behind Disease That Could Radically Change Treatment Research

We may have been mistaken when it comes to what causes Alzheimer's disease......»»

Category: topSource: newsweekJan 24th, 2018

A Cure for HIV? Cancer-Killing Immunotherapy Could Also Fight the Virus

A treatment originally intended for HIV is now finding its way back......»»

Category: topSource: newsweekJan 3rd, 2018

Have a drinking problem? Here’s a tool for finding effective treatment.

Have a drinking problem? Here’s a tool for finding effective treatment......»»

Category: topSource: washpostJan 1st, 2018

Scientists Have Developed a Brain Implant That Can Boost Memory by 30 Percent

The device was created as a treatment for Alzheimer's but it could be a sign of things to come......»»

Category: topSource: incNov 30th, 2017

KU Med hosts trial of Novartis treatment to prevent Alzheimer"s


Category: topSource: bizjournalsNov 7th, 2017

It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)

AP/Alastair GrantThe search for an Alzheimer's disease treatment has been unsuccessful for the past 14 years.  The latest failure came in September, when Axovan.....»»

Category: topSource: businessinsiderOct 8th, 2017

Expect More Downside In Axovant Sciences

Shares of Axovant Sciences Ltd (NASDAQ: AXON) plummeted more than 70 percent after the company's late-stage trial involving its therapy for the treatment of Alzheimer's failed to meet its primary Latest Ratings for AXON Dat.....»»

Category: blogSource: benzingaOct 5th, 2017

Gene Discovery Explains Why We Relapse and Could Lead to New Treatment

The finding could lead to a drug to block these underlying factors......»»

Category: topSource: newsweekSep 27th, 2017

Alzheimer"s Drug: Promising Treatment From Axovant Fails Clinical Trial

Intepirdine did not demonstrate improvements in cognition and functioning in patients with mild-to-moderate Alzheimer's disease......»»

Category: topSource: newsweekSep 26th, 2017

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease......»»

Category: blogSource: 247wallstSep 26th, 2017

UPDATE: Axovant shares tumble 71% after late-stage trial of Alzheimer"s treatment fails to meet primary goals

Axovant Sciences Ltd. shares cratered 71% in premarket trade Tuesday, after the company said a late-stage trial of a.....»»

Category: topSource: marketwatchSep 26th, 2017

Cancer Clinical Trials: How New Search Tools Make it Easier for Patients to Find the Treatment They Need

Sometimes, a cancer patient’s best chance is getting into a clinical trial. But finding the right one can be as hard as finding an IV in a haystack......»»

Category: topSource: newsweekJul 20th, 2017

UAB finding success in new cancer trials

The University of Alabama at Birmingham's part in nationwide clinical trials and research for breast cancer treatment is helping uncover new treatments and results. Doctors at UAB, in conjunction with other university and researchers, have discov.....»»

Category: topSource: bizjournalsJun 26th, 2017

Analyst: Neurotrope"s Bryostatin-1 Trial Data Justifies Additional Studies

Shares of Neurotrope Inc (NASDAQ: NTRP), a biopharmaceutical company focused on developing a therapy called bryostatin-1 for the treatment of Alzheimer's disease, lost more than half of its value on Monday.....»»

Category: blogSource: benzingaMay 1st, 2017

Neurotrope Alzheimer"s Phase 2 Trial Data Coming On Monday

Shares of Neurotrope Inc (NASDAQ: NTRP), a clinical-stage biopharmaceutical company that develops therapies for the treatment of Alzheimer's and neurodegenerative diseases, shot higher by more than 15 percent early Friday morning. read more.....»»

Category: blogSource: benzingaApr 28th, 2017

Novartis Tests New Alzheimer"s Drugs on People Who Don"t Have the Disease

Subjects at high risk of developing Alzheimer’s—but who don’t actually have the disease—are being recruited to help test two experimental treatments from Novartis AG, in a new focus on preventive treatment......»»

Category: smallbizSource: wsjApr 22nd, 2017

Neurotrope Nears Breakthrough In New Alzheimer"s Treatment

Neurotrope Nears Breakthrough In New Alzheimer"s Treatment.....»»

Category: topSource: seekingalphaApr 3rd, 2017

Alzheimer"s drug stumbles in clinical trial, Colorado company plans to keep developing it

A Colorado biotech company’s experimental Alzheimer’s treatment didn’t help patients in a clinical trial as was hoped, but the company says that may have been the result of changing the drug’s formulation. Boulder-based Accera Inc. plans f.....»»

Category: topSource: bizjournalsFeb 28th, 2017